- Conditions
- End Stage Kidney Disease
- Interventions
- CSL300, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 166
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 3,151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Disease
- Interventions
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,049 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 67
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Retinopathy of Prematurity
- Interventions
- Goggles, Ambient Light Reduction
- Device · Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Up to 1 Day
- Timeline
- Started 1995
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Dallas, Texas • San Antonio, Texas
- Conditions
- Papillomatosis, HIV Infections
- Interventions
- Interferon-alpha, placebo
- Drug · Other
- Lead sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
- Conditions
- Focal Epilepsy
- Interventions
- BHV-7000, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Geographic Atrophy
- Interventions
- JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 826
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
- Conditions
- Alzheimer's Disease
- Interventions
- Solanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 98
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- pharmacological study, dual x-ray absorptimetry
- Other · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 51 more
- Conditions
- Platinum Resistant Ovarian Cancer
- Interventions
- Fosbretabulin tromethamine, Placebo
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- temsirolimus
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • San Antonio, Texas
- Conditions
- Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Pembrolizumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 220
- States / cities
- Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Carcinoma, Squamous Cell, Non-small-cell Lung
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Interventions
- Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 914
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
- Conditions
- Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
- Interventions
- Ketone Monoester (KE)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Carotid Artery Disease
- Interventions
- Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 19 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- SGI-110 (guadecitabine), Treatment Choice
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Advanced Metastatic (Stage IV) Colorectal Cancer
- Interventions
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
- Drug
- Lead sponsor
- Egetis Therapeutics AB (publ)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
- Conditions
- Muscle Soreness
- Interventions
- Riboflavin, Placebo
- Drug
- Lead sponsor
- Steven Moore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas